JP2024523466A5 - - Google Patents

Info

Publication number
JP2024523466A5
JP2024523466A5 JP2023578896A JP2023578896A JP2024523466A5 JP 2024523466 A5 JP2024523466 A5 JP 2024523466A5 JP 2023578896 A JP2023578896 A JP 2023578896A JP 2023578896 A JP2023578896 A JP 2023578896A JP 2024523466 A5 JP2024523466 A5 JP 2024523466A5
Authority
JP
Japan
Prior art keywords
nucleotides
positions
chain
antisense
sense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023578896A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024523466A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/034297 external-priority patent/WO2022271666A1/en
Publication of JP2024523466A publication Critical patent/JP2024523466A/ja
Publication of JP2024523466A5 publication Critical patent/JP2024523466A5/ja
Pending legal-status Critical Current

Links

JP2023578896A 2021-06-22 2022-06-21 IFN-γシグナル伝達経路の調節のためのオリゴヌクレオチド Pending JP2024523466A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163213506P 2021-06-22 2021-06-22
US63/213,506 2021-06-22
US202263331563P 2022-04-15 2022-04-15
US63/331,563 2022-04-15
PCT/US2022/034297 WO2022271666A1 (en) 2021-06-22 2022-06-21 OLIGONUCLEOTIDES FOR IFN-γ SIGNALING PATHWAY MODULATION

Publications (2)

Publication Number Publication Date
JP2024523466A JP2024523466A (ja) 2024-06-28
JP2024523466A5 true JP2024523466A5 (cg-RX-API-DMAC7.html) 2025-07-01

Family

ID=84544753

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023578896A Pending JP2024523466A (ja) 2021-06-22 2022-06-21 IFN-γシグナル伝達経路の調節のためのオリゴヌクレオチド

Country Status (7)

Country Link
US (1) US20240287514A1 (cg-RX-API-DMAC7.html)
EP (1) EP4359537A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024523466A (cg-RX-API-DMAC7.html)
KR (1) KR20240040724A (cg-RX-API-DMAC7.html)
AU (1) AU2022298641A1 (cg-RX-API-DMAC7.html)
CA (1) CA3223577A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022271666A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021002440A2 (pt) 2018-08-10 2021-05-04 University Of Massachusetts oligonucleotídeos modificados visando snps
CA3174079A1 (en) 2020-05-26 2021-12-02 Anastasia Khvorova Synthetic oligonucleotides having regions of block and cluster modifications
AU2024231771A1 (en) * 2023-03-03 2025-08-28 Royal Institution For The Advancement Of Learning/Mcgill University Dendritic conjugates for the skin delivery of therapeutic oligonucleotides
KR20260026070A (ko) * 2023-06-16 2026-02-25 에프. 호프만-라 로슈 아게 Jak1 발현 조절을 위한 이중 가닥 올리고뉴클레오티드
WO2026131801A1 (en) * 2024-12-17 2026-06-25 F. Hoffmann-La Roche Ag Double stranded oligonucleotide for modulating jak1 expression

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998002558A2 (en) * 1996-07-17 1998-01-22 University Of Medicine And Dentistry Of New Jersey Chimeric receptors for jak-stat signal transduction
US6566132B1 (en) * 2001-04-26 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Interferon gamma receptor 1 expression
AU2003209340A1 (en) * 2002-01-18 2003-09-02 Bristol-Myers Squibb Company Predictor sets for tyrosine kinase pathways
EP2305813A3 (en) * 2002-11-14 2012-03-28 Dharmacon, Inc. Fuctional and hyperfunctional sirna
US20070087344A1 (en) * 2003-04-23 2007-04-19 Bioseek, Inc. Methods for characterizing signaling pathways and compounds that interact therewith
WO2006094293A2 (en) * 2005-03-03 2006-09-08 President And Fellows Of Harvard College Slim compositions and methods of use thereof
US20100247580A1 (en) * 2007-11-30 2010-09-30 Thierry Coche Method for Classifying Cancer Patients as Responder or Non-Responder to Immunotherapy
JP2014501097A (ja) * 2009-07-06 2014-01-20 アルナイラム ファーマシューティカルズ, インコーポレイテッド 生物由来物質の産生を高めるための組成物及び方法
CN107012149A (zh) * 2010-11-19 2017-08-04 艾德拉药物股份有限公司 调控基于toll‑样受体的免疫应答的免疫调节寡核苷酸(iro)化合物
BR112013029340A2 (pt) * 2011-05-16 2017-02-07 Council Scient Ind Res método para modular um processo de pigmentação nos melanócitos da pele
CN104540946A (zh) * 2012-05-16 2015-04-22 Rana医疗有限公司 用于调节utrn表达的组合物和方法
CA3133241A1 (en) * 2019-03-15 2020-09-24 University Of Massachusetts Oligonucleotides for tissue specific apoe modulation
FR3098712A1 (fr) * 2019-07-15 2021-01-22 Commissariat à l'énergie atomique et aux énergies alternatives Séquences siARN ciblant l'expression des gènes JAK1 ou JAK3 humains pour une utilisation thérapeutique

Similar Documents

Publication Publication Date Title
JP2021533804A5 (cg-RX-API-DMAC7.html)
JP2023522701A5 (cg-RX-API-DMAC7.html)
JP7129702B2 (ja) オーバーハングを有する二本鎖核酸複合体
JP2022528487A5 (cg-RX-API-DMAC7.html)
JP2023518439A5 (cg-RX-API-DMAC7.html)
JP2023550485A5 (cg-RX-API-DMAC7.html)
JP2019503394A5 (cg-RX-API-DMAC7.html)
JP2022525208A5 (cg-RX-API-DMAC7.html)
JP2021533762A5 (cg-RX-API-DMAC7.html)
AU2025201455A1 (en) Chiral control
EP3359523A2 (en) Oligonucleotide compositions and methods thereof
JP2023518268A5 (cg-RX-API-DMAC7.html)
JPH09510714A (ja) オリゴヌクレオチドn3’→p5’ホスホルアミデート:合成および化合物;ハイブリダイゼーションおよびヌクレアーゼ耐性特性
KR20020033744A (ko) 사람 eg5의 발현을 억제하는 올리고뉴클레오티드
CN105121452A (zh) 三环核苷和由其制备的寡聚化合物
CN104321334A (zh) 三环核苷及由其制备的低聚化合物
JP2025156522A (ja) 修飾ヘテロ核酸
EP2781523A1 (en) Lipophilic oligonucleotide analogs
JP7737667B2 (ja) 核酸複合体
JP6882735B2 (ja) 構造強化されたmiRNA阻害剤S−TuD
WO2024040041A1 (en) Regulation of activity of rnai molecules
CA2609365C (en) Stable and selective formation of hoogsteen-type triplexes and duplexes using twisted intercalating nucleic acids (tina) and process for the preparation of tina
EP4426839A1 (en) Lipid conjugation for targeting astrocytes of the central nervous system
EP4426432A1 (en) Lipid conjugation for targeting oligodendrocytes of the central nervous system
JP6934695B2 (ja) 核酸医薬とその使用